Clinical Data, CombinatoRx deal

Clinical Data's PGxHealth division granted CombinatoRx exclusive, worldwide rights to ATL313 for use to treat multiple myeloma (MM) and other B cell malignancies in combination with standard of care chemotherapy, such as Velcade bortezomib from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) and Revlimid lenalidomide from Celgene Corp. (NASDAQ:CELG, Summit, N.J.). Clinical Data is eligible for up to $252 million in milestones, plus royalties. CombinatoRx is responsible for preclinical and clinical development. Clinical Data has an option to co-develop ATL313 upon review of any Phase IIa data. The partners have not determined who will be responsible for commercialization. ...